{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007138","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.204136+00:00","generated_at":"2026-06-18T05:36:15.208465+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Frequency Therapeutics discontinues hearing programs, cuts 55% staff after Phase 2b miss, shifts to MS remyelination","bullets":["FX-322-208 Phase 2b for hearing loss failed primary endpoint; company ends both FX-322 and FX-345 programs.","New focus on MS remyelination program; targets clinical development initiation in first half of 2024.","Restructuring reduces workforce by ~55%, completed by end of April 2023; cash runway extended into 2025.","Q4 2022 net loss $17.4M; full year net loss $81.6M; cash, equivalents & marketable securities $83.1M at Dec 31, 2022.","CEO David Lucchino returned from medical leave on March 1, 2023 and resumed all prior duties."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007138","json":"https://secwatch.observer/filing/0000950170-23-007138.json","markdown":"https://secwatch.observer/filing/0000950170-23-007138.md","text":"https://secwatch.observer/filing/0000950170-23-007138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023007138/0000950170-23-007138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023007138/freq-20230310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:36:15.208465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b45ef42158df18963bd74f7779e71c5847a92017","claim":"Korro Bio, Inc. reported Fourth Quarter and Full Year 2022 results: net income Net loss was $17.4 million for the three months ended December 31, 2022, as compared to $21.5 million for the comparable.","evidence_excerpt":"Net loss was $17.4 million for the three months ended December 31, 2022, as compared to $21.5 million for the comparable period of 2021. Net loss was $81.6 million for the full year ended December 31, 2022, as compared to $84.7 million for the comparable period of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023007138/0000950170-23-007138-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter and Full Year 2022"},{"label":"Net income","value":"Net loss was $17.4 million for the three months ended December 31, 2022, as compared to $21.5 million for the comparable"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}